<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4645262</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P152</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Gilbert</surname><given-names>Jill</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Le Tourneau</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Mehanna</surname><given-names>Hisham</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Fayette</surname><given-names>Jerome</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Goswami</surname><given-names>Trishna</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Emeribe</surname><given-names>Ugochi</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Jarkowski</surname><given-names>Anthony</given-names><suffix>III</suffix></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Melillo</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Siu</surname><given-names>Lilian L</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib></contrib-group><aff id="I1"><label>1</label>Vanderbilt University, Nashville, TN, USA</aff><aff id="I2"><label>2</label>Department of Medical Oncology, Institut Curie, Paris &#x00026; Saint-Cloud, France</aff><aff id="I3"><label>3</label>Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, UK</aff><aff id="I4"><label>4</label>Centre L&#x000e9;on B&#x000e9;rard, University of Lyon, Lyon, France</aff><aff id="I5"><label>5</label>AstraZeneca, Gaithersburg, MD, USA</aff><aff id="I6"><label>6</label>Princess Margaret Cancer Centre, Toronto, ON, Canada</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P152</fpage><lpage>P152</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Gilbert et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Gilbert et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P152"/><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>First-line palliative treatment for patients with R/M SCCHN includes platinum-based chemotherapy. There are no standard second-line options upon relapse and median survival is limited. In SCCHN, tumors create a highly immunosuppressive environment and evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) axis, making immunotherapy an attractive option to study in this disease. Durvalumab (MEDI4736) is a selective, high affinity human IgG1 mAb that blocks PD-L1 binding to PD-1 (IC<sub>50</sub> 0.1 nM) and CD80 (IC<sub>50</sub> 0.04 nM) that has shown promising antitumor activity in the SCCHN cohort of a Phase I/II study (NCT01693562). Tremelimumab is a selective human IgG2 mAb inhibitor of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) that has been combined with durvalumab in a Phase Ib study in patients with NSCLC (NCT02000947), with encouraging clinical activity and a manageable safety profile. While anti-PD-1/PD-L1 monotherapy may be associated with greater clinical benefit in patients with PD-L1<sup>+</sup> tumors, combination therapy has clinical activity in both PD-L1<sup>+</sup> and PD-L1<sup>&#x02013;</sup> patients in several solid tumors, enhancing the antitumor activity of anti-PD-1/PD-L1 agents in patients with PD-L1<sup>&#x02013;</sup> tumors. The PD-L1 and CTLA-4 pathways are non-redundant and preclinical data indicate targeting both may induce synergistic antitumor effects. Here we describe the CONDOR study (NCT02319044), a Phase II study to determine the efficacy and safety of durvalumab monotherapy, tremelimumab monotherapy, and their combination in PD-L1<sup>&#x02013;</sup> R/M SCCHN patients who have failed prior platinumtherapy.</p></sec><sec><title>Methods</title><p>This is a randomized, open-label, multicenter, global, Phase II study in immunotherapy-na&#x000ef;ve patients with PD-L1<sup>&#x02013;</sup> R/M SCCHN who have progressed during or after treatment with a platinum-containing regimen for R/M disease. Patients with tumoral PD-L1 expression below a pre-specified cut-off level of &#x0003c; 25% tumor cells with membrane staining, as determined by an immunohistochemistry assay, are deemed PD-L1<sup>&#x02013;</sup>. Patients (N=240) will be randomized 1:1:2 to receive durvalumab (10 mg/kg IV) monotherapy; tremelimumab (10 mg/kg IV) monotherapy; or durvalumab (20 mg/kg IV) plus tremelimumab (1 mg/kg IV) combination therapy for up to 12 months (Figure <xref ref-type="fig" rid="F1">1</xref>). Stratification factors include human papillomavirus (HPV) and smoking history. The primary endpoint is objective response rate (ORR; RECIST v1.1), based on independent central review. Secondary endpoints will further assess disease control rate, duration of response, progression-free survival, and overall survival; safety (CTCAE v4.03) and tolerability; and health-related quality of life. Exploratory outcomes include pharmacokinetics, immunogenicity, and potential biomarkers of response to treatment. Recruitment is ongoing.</p><fig id="F1" position="float"><label>Figure 1</label><graphic xlink:href="2051-1426-3-S2-P152-1"/></fig></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier NCT02319044.</p></sec></body></article>